Rigel Pharmaceuticals, Inc. (RIGL) Revenue by Segment & Business Profile
Product was 85.1% of Rigel Pharmaceuticals, Inc.'s revenue across the 3 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RIGLRigel Pharmaceuticals, Inc.Follow RIGL — free
—
Price chart with a free account
- Market cap
- 899.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
What the company does
Rigel Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 3 business lines: Product (85%), Royalty Delivery Of Drug Supplies And Others (10%), Development Milestones (5%). Trailing twelve-month revenue: $276.8 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Commercial therapies
Rigel Pharmaceuticals, Inc. — questions
- What does Rigel Pharmaceuticals, Inc. do?
- Rigel Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 3 business lines: Product (85%), Royalty Delivery Of Drug Supplies And Others (10%), Development Milestones (5%). Trailing twelve-month revenue: $276.8 million as of 2026-06-30.
- How does Rigel Pharmaceuticals, Inc. make money?
- By the lines it reports in its SEC filings: Product 85.1%, Royalty Delivery Of Drug Supplies And Others 9.8%, Development Milestones 5.1% of revenue.
Every figure on this page comes from Rigel Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.